CMPS 250117 2.50C (CMPS250117C2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CMPS250117C2500

Watchlist

2.10
+0.40+23.53%

15min DelayClose Jan 3 16:00 ET

2.10High1.90Low

Intraday

5D
Daily

News

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index
BenzingaDec 18, 2024 06:31 ET
Earnings Week Ahead: FDX, NKE, CCL, BB, ACN, MU, and More
Seeking AlphaDec 13, 2024 15:50 ET
Compass Pathways to Participate in December Investor Conferences
BusinesswireNov 25, 2024 16:00 ET
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
BenzingaNov 25, 2024 14:50 ET
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
MT NewswiresNov 21, 2024 11:20 ET
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
BenzingaNov 15, 2024 10:12 ET

Comments

Stock_Drift

Dec 18, 2024 05:51

$COMPASS Pathways (CMPS.US)$

IDKWTFIMDOING

Jul 22, 2024 04:21

$COMPASS Pathways (CMPS.US)$
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

Jaguar8

May 8, 2024 05:31

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Jaguar8

May 2, 2024 06:00

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Moomoo AI

Jan 3, 2024 10:34

Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.

Why One Backer of MDMA Therapy Sees 'Exponential' Growth Following FDA Approval This Year